trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['paradigm']
the #oncoalerttoptweet day 3 #asco22 tweet breathtaking results from db0 presented by shaun modi benefit for t-dxd irrespective of subtype &amp; 1+/2+ ihc results paradigm shift that breaks through traditional subgroup classification best, 
?? Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees ?? We are #OncoAlert ??